Change search
Refine search result
12 1 - 50 of 98
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Adamina, Michel
    et al.
    Cantonal Hosp Winterthur, Switzerland; Univ Basel, Switzerland.
    Bonovas, Stefanos
    Humanitas Univ, Italy; Humanitas Clin and Res Ctr, Italy.
    Raine, Tim
    Cambridge Univ Hosp NHS Fdn Trust, England.
    Spinelli, Antonino
    Humanitas Univ, Italy.
    Warusavitarne, Janindra
    Imperial Coll London, England.
    Armuzzi, Alessandro
    Univ Cattolica Sacro Cuore, Italy.
    Bachmann, Oliver
    Siloah St Trudpert Hosp, Germany.
    Bager, Palle
    Aarhus Univ Hosp, Denmark.
    Biancone, Livia
    Univ Tor Vergata Rome, Italy.
    Bokemeyer, Bernd
    Gastroenterol Practice Minden, Germany.
    Bossuyt, Peter
    Imelda Gen Hosp, Belgium.
    Burisch, Johan
    Univ Copenhagen, Denmark.
    Collins, Paul
    Royal Liverpool Univ Hosp, England.
    Doherty, Glen
    St Vincents Univ Hosp, Ireland; St Vincents Univ Hosp, Ireland.
    El-Hussuna, Alaa
    Aalborg Univ Hosp, Denmark.
    Ellul, Pierre
    Mater Dei Hosp, Malta.
    Fiorino, Gionata
    Humanitas Univ, Italy; Humanitas Clin and Res Ctr, Italy.
    Frei-Lanter, Cornelia
    Hosp Zollikerberg, Switzerland.
    Furfaro, Federica
    Humanitas Clin and Res Ctr, Italy.
    Gingert, Christian
    Cantonal Hosp Winterthur, Switzerland; Univ Witten Herdecke, Germany.
    Gionchetti, Paolo
    Univ Bologna, Italy.
    Gisbert, Javier P.
    Univ Autonoma Madrid, Spain.
    Gomollon, Fernando
    Hosp Cli Univ Lozano Blesa, Spain.
    Lorenzo, Marien Gonzalez
    Humanitas Univ, Italy.
    Gordon, Hannah
    Barts Hlth NHS Trust, England.
    Hlavaty, Tibor
    Comenius Univ, Slovakia; Comenius Univ, Slovakia.
    Juillerat, Pascal
    Univ Hosp Bern, Switzerland.
    Katsanos, Konstantinos
    Univ and Med Sch Ioannina, Greece.
    Kopylov, Uri
    Tel HaShomer Sheba Med Ctr, Israel; Sackler Med Sch, Israel.
    Krustins, Eduards
    Riga Stradins Univ, Latvia.
    Kucharzik, Torsten
    Hosp Luneburg, Germany.
    Lytras, Theodore
    Natl Publ Hlth Org, Greece.
    Maaser, Christian
    Hosp Luneburg, Germany.
    Magro, Fernando
    Dept Pharmacol and Therapeut, Portugal; Univ Porto, Portugal.
    Marshall, John Kenneth
    McMaster Univ, Canada; McMaster Univ, Canada.
    Myrelid, Pär
    Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Pellino, Gianluca
    Univ Campania Luigi Vanvitelli, Italy.
    Rosa, Isadora
    IPOLFG, Portugal.
    Sabino, Joao
    Katholieke Univ Leuven, Belgium.
    Savarino, Edoardo
    Univ Padua, Italy.
    Stassen, Laurents
    Maastricht Univ Med Ctr, Netherlands.
    Torres, Joana
    Hosp Beatriz Angelo, Portugal.
    Uzzan, Mathieu
    Beaujon Hosp, France.
    Vavricka, Stephan
    Univ Hosp, Switzerland.
    Verstockt, Bram
    Katholieke Univ Leuven, Belgium; Katholieke Univ Leuven, Belgium.
    Zmora, Oded
    Shamir Med Ctr Assaf Harofe, Israel.
    ECCO Guidelines on Therapeutics in Crohns Disease: Surgical Treatment2020In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 14, no 2, p. 155-168Article in journal (Refereed)
    Abstract [en]

    This article is the second in a series of two publications relating to the European Crohns and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohns disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohns disease and an update of previous guidelines.

  • 2.
    Adams, A.
    et al.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Kalla, R.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, S.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Bonfiglio, F.
    BioCruces Health Research Institue, Bilbao, Spain.
    Nimmo, E.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Kennedy, N.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Ventham, N.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, M.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Ricanek, P.
    Department of Gastroenterology, Akershus University, Akershus, Norway.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Söderholm, J.
    Department of Surgery, Linköping University Hospital, Linköping, Sweden;.
    Pierik, M.
    Department of Gastroenterology and Hepatology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands.
    Törkvist, L.
    Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
    Gomollon, F.
    University Hospital Clinic Lozano Blesa, Zaragoza, Spain.
    Gut, I.
    CNAG-CRG Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
    Jahnsen, J.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Satsangi, J.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S108-S108Article in journal (Refereed)
  • 3.
    Al-Saffar, Anas K.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology. Baghdad Univ, Coll Vet Medicine, Dept Surg & Obstet, Baghdad, Iraq..
    Halim, Md Abdul
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Hall, G.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Hellström, Per M.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Webb, Dominic-Luc
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Small intestinal lactulose and sucralose hyper-permeability in inflammatory bowel disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, p. S124-S124Article in journal (Other academic)
  • 4.
    Amcoff, K.
    et al.
    Orebro Univ, Dept Gastroenterol, Fac Med & Hlth, Orebro, Sweden..
    Cao, Y.
    Univ Orebro, Sch Med Sci, Clin Epidemiol & Biostat, Orebro, Sweden..
    Zhulina, Y.
    Orebro Univ, Dept Gastroenterol, Fac Med & Hlth, Orebro, Sweden..
    Lampinen, Maria
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Halfvarson, J.
    Orebro Univ, Dept Gastroenterol, Fac Med & Hlth, Orebro, Sweden..
    Carlson, Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Prognostic significance of eosinophil granule proteins in inflammatory bowel disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, p. S181-S182Article in journal (Other academic)
  • 5.
    Amcoff, Karin
    et al.
    Örebro University, School of Medical Sciences.
    Cao, Yang
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Zhulina, Yaroslava
    Örebro University Hospital. Örebro University, School of Medical Sciences.
    Lampinen, M.
    Dept Med Sci, Uppsala Univ, Uppsala, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Carlson, M.
    Dept Med Sci, Uppsala Univ, Uppsala, Sweden.
    Prognostic significance of eosinophil granule proteins in inflammatory bowel disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S181-S182Article in journal (Other academic)
  • 6.
    Amcoff, Karin
    et al.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Joossens, Marie
    Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit, Leuven,Belgium; VIB Center for the Biology of Disease, Leuven, Belgium; Microbiology Unit, Faculty of Sciences and Bioengineering Sciences, Vrije Universiteit, Brussels, Belgium.
    Pierik, Marie J.
    Gastroenterology, University Hospital Maastricht, Maastricht, The Netherlands.
    Jonkers, Daisy
    Gastroenterology, University Hospital Maastricht, Maastricht, The Netherlands.
    Bohr, Johan
    Örebro University, School of Health Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Joossens, Sofie
    Gastroenterology, Catholic University of Leuven (KUL), Leuven, Belgium.
    Romberg-Camps, Mariëlle
    Department of Gastroenterology-Hepatology, Zuyderland Medical Center, Sittard, Netherlands.
    Nyhlin, Nils
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Wickbom, Anna
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Rutgeerts, Paul J.
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
    Tysk, Curt
    Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Bodin, Lennart
    Institute of Environmental Medicine, Unit of Intervention and Implementation Research, Karolinska Institute, Stockholm, Sweden.
    Colombel, Jean-Frederic
    Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York NY, USA.
    Vermeire, Severine
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no 6, p. 695-702Article in journal (Refereed)
    Abstract [en]

    Background and Aims: An adaptive immunological response to microbial antigens has been observed in Crohn's disease (CD). Intriguingly, this serological response precedes the diagnosis in some patients and has also been observed in healthy relatives. We aimed to determine whether genetic factors are implicated in this response in a CD twin cohort.

    Methods: In total, 82 twin pairs (Leuven n = 13, Maastricht n = 8, Örebro n = 61) took part: 81 pairs with CD (concordant monozygotic n = 16, discordant monozygotic n = 22, concordant dizygotic n = 3, discordant dizygotic n = 40) and 1 monozygotic pair with both CD and ulcerative colitis. Serology for Pseudomonas fluorescens-related protein (anti-I2), Escherichia coli outer membrane porin C (anti-OmpC), CBir1flagellin (anti-CBir1) and antibodies to oligomannan (anti-Saccharomyces cerevisiae antibody [ASCA]) was determined by standardized enzyme-linked immunoassay.

    Results: All markers were more often present in CD twins than in their healthy twin siblings. Using the intraclass correlation coefficient (ICC), agreements in concentrations of anti-OmpC and anti-I2 were observed in discordant monozygotic but not in discordant dizygotic twin pairs with CD (anti-OmpC, ICC 0.80 and -0.02, respectively) and (anti-I2, ICC 0.56 and 0.05, respectively). In contrast, no agreements were found in anti-CBir, immunoglobulin (Ig) G ASCA and ASCA IgA.

    Conclusions: We show that anti-I2 and anti-CBir1 statuses have specificity for CD and confirm previous reported specificities for anti-OmpC and ASCA. Based on quantitative analyses and observed ICCs, genetics seems to predispose to the anti-OmpC and anti-I2 response but less to ASCA and anti-CBir1 responses.

  • 7. Andersen, Vibeke
    et al.
    Chan, Simon
    Luben, Robert
    Khaw, Kay-Tee
    Olsen, Anja
    Tjonneland, Anne
    Kaaks, R.
    Grip, Olof
    Bergmann, M. M.
    Boeing, H.
    Hultdin, Johan
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Karling, Pontus
    Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Section of Medicine.
    Overvad, Kim
    Oldenburg, Bas
    Opstelten, Jorrit
    Boutron-Ruault, Marie-Christine
    Carbonnel, Franck
    Racine, Antoine
    Key, Timothy
    Masala, Giovanna
    Palli, Domenico
    Tumino, R.
    Trichopoulou, A.
    Riboli, Elio
    Hart, Andrew
    Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD)2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no 2, p. 129-136Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Population-based prospective cohort studies investigating fibre intake and development of inflammatory bowel disease are lacking. Our aim was to investigate the association between fibre intake and the development of Crohn's disease [CD] and ulcerative colitis [UC] in a large European population.

    Methods: In total, 401 326 participants, aged 20-80 years, were recruited in eight countries in Europe between 1991 and 1998. At baseline, fibre intake [total fibres, fibres from fruit, vegetables and cereals] was recorded using food frequency questionnaires. The cohort was monitored for the development of inflammatory bowel disease. Each case was matched with four controls and odds ratios [ORs] for the exposures were calculated using conditional logistic regression. Sensitivity analyses according to smoking status were computed.

    Results: In total, 104 and 221 participants developed incident CD and UC, respectively. For both CD and UC, there were no statistically significant associations with either quartiles, or trends across quartiles, for total fibre or any of the individual sources. The associations were not affected by adjusting for smoking and energy intake. Stratification according to smoking status showed null findings apart from an inverse association with cereal fibre and CD in non-smokers [Quartile 4 vs 1 OR = 0.12, 95% confidence interval = 0.02-0.75, p = 0.023, OR trend across quartiles = 0.50, 95% confidence interval = 0.29-0.86, p = 0.017].

    Conclusion: The results do not support the hypothesis that dietary fibre is involved in the aetiology of UC, although future work should investigate whether there may be a protective effect of specific types of fibre according to smoking status in CD.

  • 8.
    Andersson, Erik
    et al.
    Örebro University, School of Medical Sciences.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences.
    Kruse, Robert
    Örebro University, School of Medical Sciences.
    D'Amato, M.
    Department of Medicine, Karolinska Institutet Solna, Stockholm, Sweden.
    Repsilber, Dirk
    Örebro University, School of Medical Sciences.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Inflammatory biomarkers in serum discriminate Crohn's disease and ulcerative colitis from healthy controls2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no Suppl. 1, p. S86-S87Article in journal (Other academic)
  • 9.
    Andersson, Peter
    et al.
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Norblad, Rickard
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences.
    Söderholm, Johan D
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Myrelid, Pär
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis - a single institution experience2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no 7, p. 582-589Article in journal (Refereed)
    Abstract [en]

    INTRODUCTION:

    Ileal pouch anal anastomosis (IPAA) is the standard procedure for reconstruction after colectomy for ulcerative colitis (UC). However, ileorectal anastomosis (IRA) as an alternative has, recently experienced a revival. This study from a single center compares the clinical outcomes of these procedures.

    METHODS:

    From 1992 to 2006, 253 patients consecutively underwent either IRA (n=105) or IPAA (n=148). Selection to either procedure was determined on the basis of rectal inflammation, presence of dysplasia/cancer or patient preferences. Patient-records were retrospectively evaluated. Mean follow-up time was 5.4 and 6.3 years respectively.

    RESULTS:

    Major postoperative complications occurred in 12.4% of patients after IRA and in 12.8% after IPAA (ns). Complications of any kind after IRA or IPAA, even including subsequent stoma-closure, occurred in 23.8% and 39.9% respectively (p<0.01). Estimated cumulative failure rates after 5 and 10 years were 10.1% and 24.1% for IRA and 6.1% and 18.6% for IPAA respectively (ns). The most common cause for failure was intractable proctitis (4.8%) and unspecified dysfunction (4.8%) respectively. At follow-up 76.9% of patients with IRA had proctitis and 34.1% with IPAA had pouchitis. Estimated cumulative cancer-risk after 10, 20 and 25 year duration of disease was 0.0%, 2.1% and 8.7% for IRA. Figures for IPAA were 0.7%, 1.8% and 1.8% (ns).

    CONCLUSION:

    Failure-rates did not significantly differ between patients operated with IRA or IPAA. Patients operated with IPAA had a higher cumulative number of postoperative complications. The high long-term cancer-risk after IRA indicates that this procedure should be an interim solution in younger patients.

  • 10.
    Björkqvist, Olle
    et al.
    Örebro University, School of Medical Sciences.
    Repsilber, Dirk
    Örebro University, School of Medical Sciences.
    Seifert, M.
    Microbiol Tumor & Cell Biol, Karolinska Inst, Stockholm, Sweden.
    Engstrand, L.
    Microbiol Tumor & Cell Biol, Karolinska Inst, Stockholm, Sweden.
    Rangel, Ignacio
    Örebro University, School of Medical Sciences.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn's disease: A longitudinal study2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S468-S469Article in journal (Other academic)
  • 11.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Andersen, V.
    Dept Med, Viborg Reg Hosp, Viborg, Denmark; Dept Med, Hosp Southern Jutland, Aabenraa, Denmark.
    Cukovic-Cavka, S.
    Sch Med, Div Gastroenterol & Hepatol, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    D'Inca, R.
    Dept Surg Oncol & Gastroenterol, Azienda Osped Padova, Padua, Italy.
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Porto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Porto, Portugal.; Inst Pharmacol & Therapeut, Oporto Med Sch, Porto, Portugal.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Kievit, L.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Valpiani, D.
    Dept Gastroenterol & Digest Endoscopy, Morgagni Hosp, Forli, Italy.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp, Ioannina, Greece; Gastroenterol Unit, Ioannina, Greece.
    Vegh, Z.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Dahlerup, J. F.
    Dept Gastroenterol & Hepatol, Aarhus Univ Hosp, Aarhus, Denmark.
    Fumery, M.
    Epimad Registry, Gastroenterol Unit, Amiens Univ & Hosp, Amiens, France.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Belousova, E.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Isl, Torshavn, Denmark.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm Republ Moldova, Kishinev, Moldova.
    Ellul, P.
    Div Gastroenterol, Mater Hosp, L Imsida, Malta.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Oksanen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Giannotta, M.
    Dept Gastroenterol, AOU Careggi Reg Referral Ctr Inflammatory Bowel D, Florence, Italy.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia.
    Odes, S.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Immunomodulators reduce the risk of surgery and hospitalisation in Crohn's disease in a prospective European population-based inception cohort: the Epi-IBD cohort2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S42-S43Article in journal (Other academic)
  • 12.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Ellul, P.
    Div Gastroenterol, Mater Dei Hosp, L Imsida, Malta.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Kaimakliotis, I.
    D'Inca, R.
    Dept Surg Oncol & Gastroenterol, Azienda Osped Padova, Padua, Italy.
    Andersen, V.
    Med Dept, Viborg Reg Hosp, Viborg, Denmark; Med Dept, Hosp Southern Jutland, Aabenraa, Denmark.
    Belousova, E.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Hernandez, V.
    Gastroenterol Dept, Complexo Hosp Univ Vigo, Vigo, Spain.
    Vegh, Z.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm Republ Moldova, Kishinev, Moldova.
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Porto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Porto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Porto, Portugal.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ of Hlth Sci, Kaunas, Lithuania.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Kievit, L.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Goldis, A.
    Clin Gastroenterol, Univ Med Victor Babes, Timisoara, Romania.
    Dahlerup, J. F.
    Dept Hepatol & Gastroenterol, Aarhus Univ Hosp, Aarhus, Denmark.
    Oksanen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Cukovic-Cavka, S.
    Div Gastroenterol & Hepatol, Sch Med, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    Fumery, M.
    Gastroenterol Unit, Epimad Registry, Amiens Hosp & Univ, Amiens, France.
    Odes, S.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Nielsen, K. R.
    Med Dept, Natl Hosp Faroe Isl, Torshavn, Denmark.
    Valpiani, D.
    Dept Gastroenterol & Digest Endoscopy, Morgagni Hosp, Forli, Italy.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Giannotta, M.
    Reg Referral Ctr Inflammatory Bowel D, Dept Gastroenterol, AOU Careggi Florence, Italy.
    Salupere, R.
    Div Endocrinol & Gastroenterol, Tartu Univ Hosp, Tartu, Estonia.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp Ioannina, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp Ioannina, Ioannina, Greece.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort-the Epi-IBD cohort2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S523-S524Article in journal (Other academic)
  • 13.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Gerdes, U.
    Ctr Qual, Region Southern Denmark, Middelfart, Denmark; Inst Reg Hlth Res, Univ Southern Denmark, Odense, Denmark.
    Almer, S.
    Dept Gastroenterol, University Hospital Linköping, County Council Östergötland, Linköping, Sweden.
    Cukovic-Cavka, S.
    Sch Med, Div Gastroenterol & Hepatol, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    Sebastian, S.
    Hull Royal Infirm, Hull & East Yorkshire NHS Trust, Kingston Upon Hull, England; Hull & York Med Sch, Kingston Upon Hull, England.
    Kaimakliotis, I.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Isl, Torshavn, Denmark; Genet Biobank, Torshavn, Faroe Islands, Danmark.
    Manninen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp, Ioannina, Greece.
    Odes, S.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Andersen, V.
    Dept Med, Viborg Reg Hosp, Viborg, Denmark; Dept Med, Hosp Southern Jutland, Aabenraa, Denmark.
    D'Inca, R.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm Republ Moldova, Kishinev, Moldova.
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Vinding, K. Kofod
    Dept Med, Amager Hosp, Amager, Denmark.
    Belousova, E.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Ladefoged, K.
    Dept Med, Dronning Ingrids Hosp, Nuuk, Greenland.
    Bailey, Y.
    Dept Gastroenterol, Adelaide & Meath Hosp, Trinity College Dublin, Dublin, Ireland.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Shonova, O.
    Dept Gastroenterol, Nemocnice Ceske Budejovice, Ceske Budejovice, Czech Republic.
    Hoivik, M. L.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Moum, B.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Dahlerup, J. F.
    Dept Gastroenterol & Hepatol, Aarhus Univ Hosp, Aarhus, Denmark.
    Frequency of anaemia and anaemia subtypes in east-west European inception cohort: an ECCO-EpiCom cohort study2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no Suppl. 1, p. S453-S454Article in journal (Other academic)
  • 14.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark..
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastronterology, Örebro University Hospital, Örebro, Sweden.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus..
    Valpiani, D.
    Dept Gastroenterol & Digest Endoscopy, Morgagni Hosp, Forli, Italy.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ Prague, Prague, Czech Republic.
    Kievit, L.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Dahlerup, J. F.
    Dept Gastroenterol & Hepatol, Aarhus Univ Hosp, Aarhus, Denmark.
    Fumery, M.
    Gastroenterol Unit, Epimad Registry, Amiens Univ & Hosp, Amiens, France.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Isl, Torshavn, Denmark.
    Giannotta, M.
    Dept Gastroenterol, AOU Careggi, Regional Referral Centre of Inflammatory Bowel, Florence, Italy.
    Oksanen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp, Ioannina, Greece.
    Vegh, Z.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Ellul, P.
    Div Gastroenterol, Mater Dei Hosp, LImsida, Malta.
    Schwartz, D.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Cukovic-Cavka, S.
    Sch Med, Div Gastroenterol & Hepatol, Univ Hosp Ctr , Univ Zagreb, Zagreb, Croatia.
    D'Inca, R.
    Dept Surg Oncol & Gastroenterol, Azienda Osped Padova, Padua, Italy.
    Turcan, S.
    Dept Gastroenterol, State Univ Med Pharm, Kishinev, Moldova.
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark..
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Change in Crohn's disease behavior in a prospective European population-based inception cohort - the ECCO-EpiCom cohort2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S452-S453Article in journal (Refereed)
  • 15.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Valpiani, D.
    Dept Gastroenterol & Digest Endoscopy, Morgagni Hosp, Forli, Italy.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Duricova, D.
    IBD Ctr ISCARE, Prague, Charles Univ Prague, Czech Republic.
    Kievit, L.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Dahlerup, J. F.
    Dept Gastroenterol & Hepatol, Aarhus Univ Hosp, Aarhus, Denmark.
    Fumery, M.
    Epimad Registry, Gastroenterol Unit, Amiens Univ & Hosp, Amiens, France.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Islands, Torshavn, Denmark..
    Giannotta, M.
    Inflammatory Bowel D, Dept Gastroenterol, AOU Careggi Regional Referral Centre, Florence, Italy.
    Oksanen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp Ioannina, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp Ioannina, Ioannina, Greece.
    Vegh, Z.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Ellul, P.
    Div Gastroenterol, Mater Dei Hosp, Limsida, Malta.
    Schwartz, D.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Cukovic-Cavka, S.
    Sch Med, Div Gastroenterol & Hepatol, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    D'Inca, R.
    Dept Surg Oncol & Gastroenterol, Azienda Osped Padova, Padua, Italy.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm, Kishinev, Moldova..
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Disease course during the first five years following diagnosis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S435-S436Article in journal (Refereed)
  • 16.
    Burisch, J.
    et al.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastronterology, Örebro University Hospital, Örebro, Sweden.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Valpiani, D.
    Dept Gastroenterol & Digest Endoscopy, Morgagni Hosp, Forli, Italy.
    Pedersen, N.
    Dept Gastroenterol, Slagelse Hosp, Slagelse, Denmark.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ Prague, Prague, Czech Republic.
    Kievit, L.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Dahlerup, J. F.
    Dept Gastroenterol & Hepatol, Aarhus Univ Hosp, Aarhus, Denmark.
    Fumery, M.
    Epimad Registry, Gastroenterol Unit, Amiens Univ & Hosp, Amiens, France.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia.
    Arebi, N.
    Gastroenterol, St Marks Hosp, London, England.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Islands, Torshavn, Denmark.
    Giannotta, M.
    Dept Gastroenterol, AOU Careggi, Regional Referral Centre of Inflammatory Bowel Disease, Florence, Italy.
    Oksanen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Div Internal Med 1, Univ Hosp Ioannina, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp, Ioannina, Greece.
    Vegh, Z.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Ellul, P.
    Div Gastroenterol, Mater Dei Hosp, Limsida, Malta.
    Schwartz, D.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev,Beer Sheva, Israel.
    Cukovic-Cavka, S.
    Sch Med, Div Gastroenterol & Hepatol, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    D'Inca, R.
    Dept Surg Oncol & Gastroenterol, Azienda Osped Padova, Padua, Italy.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm Republ Moldova, Kishinev, Moldova.
    Magro, F.
    Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Munkholm, P.
    Dept Gastroenterol, North Zealand Univ Hosp, Frederikssund, Denmark.
    The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S436-S436Article in journal (Refereed)
  • 17.
    Burisch, J.
    et al.
    Gastrounit, Medical section, Hvidovre University Hospital, Hvidovre, Denmark.
    Kaimakliotis, I.
    Nicosia Private practice, Nicosia, Cyprus.
    Duricova, D.
    IBD Center ISCARE, Charles University, Prague, Czech Republic.
    Kievit, L.
    Department of medicine, Herning Central Hospital, Herning, Denmark.
    Dahlerup, J. F.
    Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
    Salupere, R.
    Division of Endocrinology and Gastroenterology, Tartu University Hospital, Tartu, Estonia.
    Nielsen, K. R.
    Medical Department, The National Hospital of the Faroe Islands, Thorshavn, Denmark.
    Manninen, P.
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
    Tsianos, E. V.
    1st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece.
    Vegh, Z.
    1st Department of Medicine, Semmelweis University, Budapest, Hungary.
    Odes, S.
    Department of Gastroenterology and Hepatology, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
    D'Inca, R.
    EpiCom Northern Italy, Florence, Forlì and Padova, Italy.
    Kupcinskas, L.
    Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Turcan, S.
    Department of Gastroenterology, Chisinau, State University of Medicine and Pharmacy of the Republic of Moldova, Moldova, Republic of Moldova.
    Magro, F.
    Institute for molecular and cell biology, University of Porto, Porto, Portugal; Department of Gastroenterology, Hospital de São João, Porto, Portugal; Institute of Pharmacology and Therapeutics, Oporto Medical School, Porto, Portugal.
    Goldis, A.
    Clinic of Gastroenterology, University of Medicine Victor Babes, Timisoara, Romania.
    Hernandez, V.
    Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
    Halfvarson, Jonas
    Örebro University, School of Medicine, Örebro University, Sweden.
    Arebi, N.
    Gastroenterology, St Mark's Hospital, London, United Kingdom.
    Langholz, E.
    Department of Medical Gastroenterology, Gentofte Hospital, Copenhagen, Denmark.
    Lakatos, P. L.
    1st Department of Medicine, Semmelweis University, Budapest, Hungary.
    Munkholm, P.
    Department of gastroenterology, Herlev University Hospital, Herlev, Denmark.
    EpiCom Northern Italy, Group author
    Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals-3-year follow-up of the ECCO-EpiCom cohort2015In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, p. S5-S6Article in journal (Other academic)
  • 18.
    Burisch, J.
    et al.
    Dept Gastroenterol, Herlev Univ Hosp, Herlev, Denmark.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Thorsgaard, N.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Andersen, V.
    Dept Med, Viborg Reg Hosp, Viborg, Denmark; Inst Reg Hlth Res, Univ Southern Denmark, Odense, Denmark; Dept Med, Hosp Southern Jutland, Aabenraa, Denmark.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Islands, Torshavn, Denmark.
    Tsianos, E. V.
    Div Internal Med 1, Univ Hosp, Ioannina, Greece; Hepatogastroenterol Unit, Ioannina, Greece.
    Ladefoged, K.
    Dept Med, Dronning Ingrids Hosp, Nuuk, Greenland.
    Bailey, Y.
    Dept Gastroenterol, Adelaide & Meath Hosp, Trinity College, Dublin, Ireland.
    D'Inca, R.
    UO Gastroenterol, Azienda Osped, Univ Padua, Padua, Italy; EpiCom Northern Italy Ctr Based Crema & Cremona, Forli, Italy; EpiCom Northern Italy Ctr Based Crema & Cremona, Reggio Emilia, Italy.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Turcan, S.
    Dept Gastroenterol, State University of Medicine and Pharmacy "Nicolae Testemitanu", Kishinev, Moldova.
    Magro, F.
    Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal; Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Belousova, E.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Hernandez, V.
    Gastroenterol, Complejo Hosp Univ Vigo, Vigo, Spain.
    Almer, S.
    Dept Gastroenterol, Uiveraity Hospital, Cty Council Östergötland, Linköping, Sweden; Div Gastroenterol & Hepatol, Karolinska Inst, Stockholm, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Dept Med 24, Div Gastroenterol, Örebro Univ Hosp, Örebro, Sweden .
    Sebastian, S.
    Hull Royal Infirm, Hull & East Yorkshire NHS Trust, Kingston Upon Hull, England; Hull & York Med Sch, Kingston Upon Hull, England.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Odes, S.
    Soroka Med Ctr, Beer Sheva, Israel; Dept Gastroenterol & Hepatol, Ben Gurion Univ Negev, Beer Sheva, Israel.
    Munkholm, P.
    Dept Gastroenterol, Herlev Univ Hosp, Herlev, Denmark.
    The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era: An ECCO-EpiCom study2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no Suppl. 1, p. S5-S6Article in journal (Refereed)
  • 19.
    Burisch, J.
    et al.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Pedersen, N.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Cukovic-Cavka, S.
    Div Gastroenterol & Hepatol, Sch Med, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    Turk, N.
    Div Gastroenterol & Hepatol, Sch Med, Univ Hosp Ctr Zagreb, Univ Zagreb, Zagreb, Croatia.
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Bortlik, M.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Shonova, O.
    Dept Gastroenterol, Hosp Ceske Budejovice, Ceske Budejovice, Czech Republic.
    Vind, I.
    Dept Med, Amager Hosp, Amager, Denmark.
    Avnstrom, S.
    Dept Med, Amager Hosp, Amager, Denmark.
    Thorsgaard, N.
    Dept Med, Herning Cent Hosp, Herning, Denmark.
    Krabbe, S.
    Dept Med, Viborg Reg Hosp, Viborg, Denmark.
    Andersen, V.
    Dept Med, Viborg Reg Hosp, Viborg, Denmark; Organ Ctr, Hosp Southern Jutland, Aabenraa, Denmark; Inst Reg Hlth Res, Univ Southern Denmark, Odense, Denmark.
    Dahlerup, J. F.
    Dept Med Hepatol & Gastroenterol, Aarhus Univ Hosp, Aarhus, Denmark.
    Kjeldsen, J.
    Dept Med Gastroenterol, Odense Univ Hosp, Odense, Denmark.
    Salupere, R.
    Olsen, J.
    Div Gastroenterol & Endocrinol, Tartu Univ Hosp, Tartu, Estonia; , Dept Med, Natl Hosp Faroe Islands, Torshavn, Denmark.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Islands, Torshavn, Denmark.
    Manninen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Collin, P.
    Dept Gastroenterol & Alimentary Tract Surg, Tampere Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Div Internal Med, Univ Hosp, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp, Ioannina, Greece.
    Tsianos, E. V.
    Div Internal Med, Univ Hosp, Ioannina, Greece; Hepatogastroenterol Unit, Univ Hosp, Ioannina, Greece.
    Ladefoged, K.
    Dept Med, Dronning Ingrids Hosp, Nuuk, Greenland.
    Lakatos, L.
    Dept Med, Semmelweis Univ, Budapest, Hungary.
    Ragnarsson, G.
    Sect Gastroenterol & Hepatol, Dept Internal Med, Natl Univ Hosp Reykjavik, Reykjavik, Iceland.
    Björnsson, E.
    Sect Gastroenterol & Hepatol, Dept Internal Med, Natl Univ Hosp Reykjavik, Reykjavik, Iceland.
    Bailey, Y.
    Dept Gastroenterol, TCD, Adelaide & Meath Hosp, Dublin, Ireland.
    O'Morain, C.
    Dept Gastroenterol, TCD, Adelaide & Meath Hosp, Dublin, Ireland.
    Schwartz, D.
    Dept Gastroenterol & Hepatol, Soroka Med Ctr, Beer Sheva, Israel; Ben Gurion Univ Negev, Beer Sheva, Israel.
    Odes, S.
    Dept Gastroenterol & Hepatol, Soroka Med Ctr, Beer Sheva, Israel; Ben Gurion Univ Negev, Beer Sheva, Israel.
    Giannotta, M.
    Gastroenterol Unit, Careggi Hosp, Florence, Italy.
    Girardin, G.
    UO Gastroenterol, Azienda Osped Univ Padova, Padua, Italy.
    Kiudelis, G.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Turcan, S.
    Dept Gastroenterol, State Univ Med & Pharm Republ Moldova, Kishinev, Moldova.
    Barros, L.
    Hosp de Vale de Sousa, Oporto, Portugal.
    Magro, F.
    Dept Gastroenterol, Hosp Sao Joao, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal; Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal.
    Lazar, D.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Nikulina, I.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Belousova, E.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Martinez-Ares, D.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Hernandez, V.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Almer, S.
    Div Gastroenterol & Hepatol, Karolinska Inst, Stockholm, Sweden; Dept Gastroenterol UHL, Cty Council Östergötland, Linköping, Sweden.
    Zhulina, Yaroslava
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Div Gastroenterol, Dept Med.
    Halfvarson, Jonas
    Örebro University Hospital. Div Gastroenterol, Dept Med.
    Arebi, N.
    St Marks Hosp, Univ London Imperial Coll Sci Technol & Med, London, England.
    Tsai, H. H.
    Hull Royal Infirm, Hull & York Med Sch, Hull & East Yorkshire NHS Trust, Kingston Upon Hull, N Humberside, England.
    Sebastian, S.
    Hull Royal Infirm, Hull & York Med Sch, Hull & East Yorkshire NHS Trust, Kingston Upon Hull, N Humberside, England.
    Lakatos, P. L.
    Dept Med, Semmelweis Univ, Budapest, Hungary.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Munkholm, P.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe: An ECCO-EpiCom study2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no 7, p. 607-616Article in journal (Refereed)
    Abstract [en]

    Background and Aims: The incidence of inflammatory bowel disease (IBD) is increasing in Eastern Europe possibly due to changes in environmental factors towards a more "westernised" standard of Living. The aim of this study was to investigate differences in exposure to environmental factors prior to diagnosis in Eastern and Western European IBD patients.

    Methods: The EpiCom cohort is a population-based, prospective inception cohort of 1560 unselected IBD patients from 31 European countries covering a background population of 10.1 million. At the time of diagnosis patients were asked to complete an 87-item questionnaire concerning environmental factors.

    Results: A total of 1182 patients (76%) answered the questionnaire, 444 (38%) had Crohn's disease (CD), 627 (53%) ulcerative colitis (UC), and 111 (9%) IBD unclassified. No geographic differences regarding smoking status, caffeine intake, use of oral contraceptives, or number of first-degree relatives with IBD were found. Sugar intake was higher in CD and UC patients from Eastern Europe than in Western Europe while fibre intake was lower (p < 0.01). Daily consumption of fast food as well as appendectomy before the age of 20 was more frequent in Eastern European than in Western European UC patients (p < 0.01). Eastern European CD and UC patients had received more vaccinations and experienced fewer childhood infections than Western European patients (p < 0.01).

    Conclusions: In this European population-based inception cohort of unselected IBD patients, Eastern and Western European patients differed in environmental factors prior to diagnosis. Eastern European patients exhibited higher occurrences of suspected risk factors for IBD included in the Western lifestyle. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

  • 20.
    Burisch, J.
    et al.
    North Zealand University Hospital, Frederikssund, Denmark.
    Vardi, H.
    Ben Gurion University of the Negev, Beer Sheva, Israel.
    Schwartz, D.
    Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel.
    Krznaric, Z.
    University Hospital Center Zagreb, Zagreb, Croatia.
    Lakatos, P. L.
    Semmelweis University, Budapest, Hungary.
    Fumery, M.
    Amiens University and Hospital, Amiens, France.
    Kupcinskas, L.
    Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Magro, F.
    Hospital de São João, Porto, Portugal.
    Belousova, E.
    Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
    Oksanen, P.
    Tampere University Hospital, Tampere, Finland.
    Arebi, N.
    Imperial College London, London, UK.
    Langholz, E.
    Herlev University Hospital, Herlev, Denmark.
    Turcan, S.
    State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova.
    D'Inca, R.
    Azienda Ospedaliera di Padova, Padova, Italy.
    Hernandez, V.
    Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
    Valpiani, D.
    Morgagni Hospital, Forli, Italy.
    Vegh, Z.
    Semmelweis University, Budapest, Hungary.
    Giannotta, M.
    Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy.
    Katsanos, K. H.
    University Hospital, Ioannina, Greece.
    Duricova, D.
    Charles University, Prague, Czech Republic.
    Nielsen, K. R.
    National Hospital of the Faroe Islands, Torshavn, Faroe Islands.
    Kievit, H. A. L.
    Herning Hospital, Herning, Denmark.
    Ellul, P.
    Mater Dei Hospital, Msida, Malta.
    Salupere, R.
    Tartu University Hospital, Tartu, Estonia.
    Goldis, A.
    University of Medicine ‘Victor Babes’, Timisoara, Romania.
    Kaimakliotis, I.
    American Gastroenterology center, Nicosia, Cyprus.
    Pedersen, N.
    Slagelse Hospital, Department of medicine, Denmark.
    Andersen, V.
    Regional Hospital of Viborg, Viborg, Denmark.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Sebastian, S.
    Hull and East Yorkshire NHS Trust, Hull, UK.
    Dahlerup, J. F.
    Aarhus University Hospital, Aarhus, Denmark.
    Munkholm, P.
    North Zealand University Hospital, Frederikssund, Denmark.
    Odes, S.
    Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel.
    Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?2019In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 13, no Suppl. 1, p. S9-S10Article in journal (Other academic)
  • 21.
    Burisch, J.
    et al.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Vegh, Z.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark; Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Pedersen, N.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Cukovic-Cavka, S.
    Univ Hosp Ctr Zagreb, Div Gastroenterol & Hepatol, Univ Zagreb Sch Med, Zagreb, Croatia.
    Turk, N.
    Univ Hosp Ctr Zagreb, Div Gastroenterol & Hepatol, Univ Zagreb Sch Med, Zagreb, Croatia.
    Kaimakliotis, I.
    Duricova, D.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Bortlik, M.
    IBD Ctr ISCARE, Charles Univ, Prague, Czech Republic.
    Shonova, O.
    Dept Gastroenterol, Hosp Ceske Budejovice, Ceske Budejovice, Czech Republic.
    Thorsgaard, N.
    Dept Med, Cent Hosp, Herning, Denmark.
    Krabbe, S.
    Dept Med, Reg Hosp, Viborg, Denmark.
    Andersen, V.
    Dept Med, Reg Hosp, Viborg, Denmark; Dept Med, Hosp Southern Jutland, Aabenraa, Denmark; Inst Reg Hlth Res, Univ Southern Denmark, Odense, Denmark.
    Dahlerup, J. F.
    Dept Med Hepatol & Gastroenterol 5, Aarhus Univ Hosp, Aarhus, Denmark.
    Kjeldsen, J.
    Dept Med Gastroenterol, Univ Hosp, Odense, Denmark.
    Salupere, R.
    Div Gastroenterol & Endocrinol, Univ Hosp, Tartu, Estonia.
    Olsen, J.
    Dept Med, Natl Hosp Faroe Isl, Torshavn, Denmark.
    Nielsen, K. R.
    Dept Med, Natl Hosp Faroe Isl, Torshavn, Denmark.
    Manninen, P.
    Dept Gastroenterol & Alimentary Tract Surg, Univ Hosp, Tampere, Finland.
    Collin, P.
    Dept Gastroenterol & Alimentary Tract Surg, Univ Hosp, Tampere, Finland.
    Katsanos, K. H.
    Sch Med, Div Internal Med 1, Univ Ioannina, Ioannina, Greece; Sch Med, Div Gastroenterol, Univ Ioannina, Ioannina, Greece.
    Tsianos, E. V.
    Sch Med, Div Internal Med 1, Univ Ioannina, Ioannina, Greece; Sch Med, Div Gastroenterol, Univ Ioannina, Ioannina, Greece.
    Ladefoged, K.
    Dept Med, Dronning Ingrids Hosp, Nuuk, Greenland.
    Ragnarsson, G.
    Sect Gastroenterol & Hepatol, Dept Internal Med, Natl Univ Hosp, Reykjavik, Iceland.
    Björnsson, E.
    Sect Gastroenterol & Hepatol, Dept Internal Med, Natl Univ Hosp, Reykjavik, Iceland.
    Bailey, Y.
    Dept Gastroenterol, Adelaide & Meath Hosp, Trinity College Dublin, Dublin, Ireland.
    O'Morain, C.
    Dept Gastroenterol, Adelaide & Meath Hosp, Trinity College Dublin, Dublin, Ireland.
    Schwartz, D.
    Odes, S.
    Dept Gastroenterol & Hepatol, Soroka Med Ctr, Beer Sheva, Israel; Ben Gurion Univ Negev, Beer Sheva, Israel .
    Politi, S. P.
    UO Med Interna & Gastroenterol, Azienda Osped Istituti Ospitalieri Cremona, Cremona, Italy; EpiCom Northern Italy Ctr, Crema Cremona, Italy; EpiCom Northern Italy Ctr, Florence, Italy; EpiCom Northern Italy Ctr, Forli, Italy; EpiCom Northern Italy Ctr, Padua, Italy; EpiCom Northern Italy Ctr, Reggio Emilia, Italy .
    Santini, A.
    Gastroenterol Unit, Careggi Hosp, Florence, Italy; EpiCom Northern Italy Ctr, Crema Cremona, Italy; EpiCom Northern Italy Ctr, Florence, Italy; EpiCom Northern Italy Ctr, Forli, Italy; EpiCom Northern Italy Ctr, Padua, Italy; EpiCom Northern Italy Ctr, Reggio Emilia, Italy .
    Kiudelis, G.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Kupcinskas, L.
    Inst Digest Res, Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
    Turcan, S.
    State Univ Med & Pharm Republ Moldova, Dept Gastroenterol, Kishinev, Moldova.
    Magro, F.
    Hosp Sao Joao, Dept Gastroenterol, Oporto, Portugal; Inst Pharmacol & Therapeut, Oporto Med Sch, Oporto, Portugal; Inst Mol & Cell Biol, Univ Porto, Oporto, Portugal.
    Barros, L.
    Hosp Vale Sousa, Oporto, Portugal.
    Lazar, D.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Goldis, A.
    Gastroenterol Clin, Univ Med Victor Babes, Timisoara, Romania.
    Nikulina, I.
    Dept Gastroenterol, Moscow Reg Res Clin Inst, Moscow, Russia.
    Belousova, E.
    Moscow Reg Res Clin Inst, Dept Gastroenterol, Moscow, Russia.
    Sanroman, L.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Martinez-Ares, D.
    Dept Gastroenterol, Complexo Hosp Univ Vigo, Vigo, Spain.
    Almer, S.
    Dept Med, Div Gastroenterol & Hepatol, Karolinska Inst, Stockholm, Sweden; Dept Gastroenterol UHL, Cty Council Ostergötland, Linköping, Sweden .
    Zhulina, Yaroslava
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Div Gastroenterol, Dept Med, Örebro Univ Hosp, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medicine, Örebro University, Sweden. Div Gastroenterol, Dept Med, Örebro Univ Hosp, Örebro, Sweden.
    Arebi, N.
    St Marks Hosp, Sir Alan Parks Physiol Unit, Univ London Imperial Coll Sci Technol & Med, London, England.
    Houston, Y.
    Hull & East Yorkshire HNS Trust, Dept Gastroenterol, Kingston Upon Hull, N Humberside, England.
    Sebastian, S.
    Hull & East Yorkshire NHS Trust, Hull Royal Infirm, Kingston Upon Hull, England; Hull & York Med Sch, Hull Royal Infirm, Kingston Upon Hull, England.
    Langholz, E.
    Dept Med Gastroenterol, Gentofte Univ Hosp, Copenhagen, Denmark.
    Lakatos, P. L.
    Dept Med 1, Semmelweis Univ, Budapest, Hungary.
    Munkholm, P.
    Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
    Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no 8, p. 811-818Article in journal (Refereed)
    Abstract [en]

    Background and Aims: The EpiCom study and inception cohort was initiated in 2010 in 31 centers from 14 Western and 8 Eastern European countries, covering a 10.1 million person background population. Our aim was to investigate whether there is a difference between Eastern and Western Europe in health care and education of patients with inflammatory bowel disease (IBD).

    Methods: A quality of care (QoC) questionnaire was developed in the EpiCom group consisting of 16 questions covering 5 items: time interval between the onset of symptoms and diagnosis, information, education, empathy and access to health care providers.

    Results: Of 1,515 patients, 947 (217 east/730 west) answered the QoC questionnaire. Only 23% of all patients had knowledge about IBD before diagnosis. In Eastern Europe, significantly more patients searched out information about IBD themselves (77% vs. 68%, p < 0.05), the main source was the Internet (92% vs. 88% p = 0.23). In Western Europe, significantly more patients were educated by nurses (19% vs. 1%, p < 0.05), while in Eastern Europe, gastroenterologists were easier to contact (80% vs. 68%, p < 0.05).

    Conclusion: Health care differed significantly between Eastern and Western Europe in all items, but satisfaction rates were high in both geographic regions. Because of the low awareness and the rising incidence of IBD, general information should be the focus of patient organizations and medical societies. In Western Europe IBD nurses play a very important role in reducing the burden of patient management. (c) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

  • 22.
    Burisch, J.
    et al.
    Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark .
    Weimers, P.
    Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark .
    Pedersen, N.
    Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark .
    Cukovic-Cavka, S.
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia .
    Vucelic, B.
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia .
    Kaimakliotis, I.
    Nicosia Private Practice, Nicosia, Cyprus.
    Duricova, D.
    IBD Center ISCARE, Charles University, Prague, Czech Republic.
    Bortlik, M.
    IBD Center ISCARE, Charles University, Prague, Czech Republic.
    Shonová, O.
    Gastroenterology Department, Hospital České Budějovice, České Budějovice, Czech Republic.
    Vind, I.
    Department of Medicine, Amager Hospital, Amager, Denmark .
    Avnstrøm, S.
    Department of Medicine, Amager Hospital, Amager, Denmark .
    Thorsgaard, N.
    Department of Medicine, Herning Central Hospital, Herning, Denmark .
    Krabbe, S.
    Medical Department, Viborg Regional Hospital, Viborg, Denmark .
    Andersen, V.
    Medical Department, Viborg Regional Hospital, Viborg, Denmark ; Medical Department, Hospital of Southern Jutland, Aabenraa, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark .
    Dahlerup, J. F.
    Department of Medicine V, Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark .
    Kjeldsen, J.
    Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark .
    Salupere, R.
    Division of Endocrinology and Gastroenterology, Tartu University Hospital, Tartu, Estonia .
    Olsen, J.
    Medical Department, The National Hospital of the Faroe Islands, Torshavn, Denmark.
    Nielsen, K. R.
    Medical Department, The National Hospital of the Faroe Islands, Torshavn, Denmark.
    Manninen, P.
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland .
    Collin, P.
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland .
    Katsanos, K. H.
    1st Division of Internal Medicine and Division of Gastroenterology, Medical School, University of Ioannina, Ioannina, Greece .
    Tsianos, E. V.
    1st Division of Internal Medicine and Division of Gastroenterology, Medical School, University of Ioannina, Ioannina, Greece .
    Ladefoged, K.
    Medical Department, Dronning Ingrids Hospital, Nuuk, Greenland .
    Lakatos, L.
    Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary .
    Ragnarsson, G.
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, The National University Hospital, Reykjavik, Iceland .
    Björnsson, E.
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, The National University Hospital, Reykjavik, Iceland .
    Bailey, Y.
    Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College Dublin, Dublin, Ireland .
    O'Morain, C.
    Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College Dublin, Dublin, Ireland .
    Schwartz, D.
    Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel ; Department of Gastroenterology and Hepatology, Ben Gurion University of the Negev, Beer Sheva, Israel.
    Odes, S.
    Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel ; Department of Gastroenterology and Hepatology, Ben Gurion University of the Negev, Beer Sheva, Israel.
    Valpiani, D.
    U.O. Gastroenterologia ed Endoscopia Digestiva, Ospedale Morgagni - Pierantoni, Forlì, Italy.
    Boni, M. C.
    U.O. Medicina 3 e Gastroenterologia, Azienda Ospedaliera Arcispedale S. Maria Nuova, Reggio Emilia, Italy .
    Jonaitis, L.
    Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania .
    Kupcinskas, L.
    Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania .
    Turcan, S.
    Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova.
    Barros, L.
    Hospital de Vale de Sousa, Porto, Portugal .
    Magro, F.
    Department of Gastroenterology, Hospital São João, Porto, Portugal; Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; IBMC - Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal.
    Lazar, D.
    Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania .
    Goldis, A.
    Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania .
    Nikulina, I.
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation .
    Belousova, E.
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation .
    Fernandez, A.
    Gastroenterology Department, POVISA Hospital, Vigo, Spain .
    Sanroman, L.
    Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain .
    Almér, S.
    Division of Gastroenterology and Hepatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden;Department of Gastroenterology/UHL, County Council of Östergötland, Linköping, Sweden.
    Zhulina, Yaroslava
    Örebro University Hospital. Department of Medicine, Division of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Medicine, Division of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Arebi, N.
    St. Mark's Hospital, Imperial College London, London, United Kingdom.
    Diggory, T.
    Hull and East Yorkshire NHS Trust, Hull and York Medical School, Hull Royal Infirmary, Hull, United Kingdom; Hull and York Medical School, Hull Royal Infirmary, Hull, United Kingdom .
    Sebastian, S.
    Hull and East Yorkshire NHS Trust, Hull and York Medical School, Hull Royal Infirmary, Hull, United Kingdom; Hull and York Medical School, Hull Royal Infirmary, Hull, United Kingdom .
    Lakatos, P. L.
    1st Department of Medicine, Semmelweis University, Budapest, Hungary .
    Langholz, E.
    Department of Medical Gastroenterology, Gentofte Hospital, Copenhagen, Denmark .
    Munkholm, P.
    Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark .
    Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease: An ECCO-EpiCom study2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no 9, p. 1030-1042Article in journal (Refereed)
    Abstract [en]

    Background & Aims: Health-related quality of life (HRQoL) is impaired in patients with Inflammatory Bowel Disease (IBD). The aim was prospectively to assess and validate the pattern of HRQoL in an unselected, population-based inception cohort of IBD patients from Eastern and Western Europe.

    Methods: The EpiCom inception cohort consists of 1560 IBD patients from 31 European centres covering a background population of approximately 10.1 million. Patients answered the disease specific Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and generic Short Form 12 (SF-12) questionnaire at diagnosis and after one year of follow-up.

    Results: In total, 1079 patients were included in this study. Crohn's disease (CD) patients mean SIBDQ scores improved from 45.3 to 55.3 in Eastern Europe and from 44.9 to 53.6 in Western Europe. SIBDQ scores for ulcerative colitis (UC) patients improved from 44.9 to 57.4 and from 48.8 to 55.7, respectively. UC patients needing surgery or biologicals had lower SIBDQ scores before and after compared to the rest, while biological therapy improved SIBDQ scores in CD. CD and UC patients in both regions improved all SF-12 scores. Only Eastern European UC patients achieved SF-12 summary scores equal to or above the normal population.

    Conclusion: Medical and surgical treatment improved HRQoL during the first year of disease. The majority of IBD patients in both Eastern and Western Europe reported a positive perception of disease-specific but not generic HRQoL. Biological therapy improved HRQoL in CD patients, while UC patients in need of surgery or biological therapy experienced lower perceptions of HRQoL than the rest.

  • 23. Burisch, Johan
    et al.
    Cukovic-Cavka, Silvija
    Kaimakliotis, Ioannis
    Shonová, Olga
    Andersen, Vibeke
    Dahlerup, Jens F
    Elkjaer, Margarita
    Langholz, Ebbe
    Pedersen, Natalia
    Salupere, Riina
    Kolho, Kaija-Leena
    Manninen, Pia
    Lakatos, Peter Laszlo
    Shuhaibar, Mary
    Odes, Selwyn
    Martinato, Matteo
    Mihu, Ion
    Magro, Fernando
    Belousova, Elena
    Fernandez, Alberto
    Almer, Sven
    Halfvarson, Jonas
    Örebro University, School of Health and Medical Sciences.
    Hart, Ailsa
    Munkholm, Pia
    Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe an EpiCom study2011In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 5, no 4, p. 342-349Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: The EpiCom-study investigates a possible East-West-gradient in Europe in the incidence of IBD and the association with environmental factors. A secured web-based database is used to facilitate and centralize data registration.

    AIM: To construct and validate a web-based inception cohort database available in both English and Russian language.

    METHOD: The EpiCom database has been constructed in collaboration with all 34 participating centers. The database was translated into Russian using forward translation, patient questionnaires were translated by simplified forward-backward translation. Data insertion implies fulfillment of international diagnostic criteria, disease activity, medical therapy, quality of life, work productivity and activity impairment, outcome of pregnancy, surgery, cancer and death. Data is secured by the WinLog3 System, developed in cooperation with the Danish Data Protection Agency. Validation of the database has been performed in two consecutive rounds, each followed by corrections in accordance with comments.

    RESULTS: The EpiCom database fulfills the requirements of the participating countries' local data security agencies by being stored at a single location. The database was found overall to be "good" or "very good" by 81% of the participants after the second validation round and the general applicability of the database was evaluated as "good" or "very good" by 77%. In the inclusion period January 1st -December 31st 2010 1336 IBD patients have been included in the database.

    CONCLUSION: A user-friendly, tailor-made and secure web-based inception cohort database has been successfully constructed, facilitating remote data input. The incidence of IBD in 23 European countries can be found at www.epicom-ecco.eu.

  • 24.
    Burisch, Johan
    et al.
    Department of Gastroenterology, Nordsjællands Hospital, University of Copenhagen, Frederikssund, Denmark.
    Katsanos, Konstantinos H.
    Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece.
    Christodoulou, Dimitrios K.
    Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece.
    Barros, Luisa
    Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal.
    Magro, Fernando
    Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal; Department of Biomedicine, Institute of Pharmacology, Faculty of Medicine of Porto University, Porto, Portugal.
    Pedersen, Natalia
    Gastroenterology Department, Slagelse Hospital, Slagelse, Denmark.
    Kjeldsen, Jens
    Gastroenterology Department, Odense University Hospital, Odense, Denmark.
    Vegh, Zsuzsanna
    First Department of Medicine, Semmelweis University, Budapest, Hungary.
    Lakatos, Peter L.
    First Department of Medicine, Semmelweis University, Budapest, Hungary; Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada.
    Eriksson, Carl
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Fumery, Mathurin
    Gastroenterology Unit, Epimad Registry, CHU Amiens Sud, Amiens University Hospital, Amiens, France.
    Gower-Rousseau, Corinne
    Public Health, Epidemiology and Economic Health, Registre Epimad, Lille University and Hospital, Lille, France; Lille Inflammation Research International Center LIRIC, Lille University, Lille, France.
    Brinar, Marko
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.
    Čuković-Čavka, Silvija
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.
    Nikulina, Inna
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
    Belousova, Elena
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
    Myers, Sally
    IBD Unit, Hull and East Yorkshire NHS Trust, Hull, UK.
    Sebastian, Shaji
    IBD Unit, Hull and East Yorkshire NHS Trust, Hull, UK.
    Kiudelis, Gediminas
    Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Kupcinskas, Limas
    Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania; Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Schwartz, Doron
    Department of Gastroenterology and Hepatology, Soroka Medical Center, Beer Sheva, Israel; Ben Gurion University of the Negev; Beer Sheva, Israel.
    Odes, Selwyn
    Department of Gastroenterology and Hepatology, Soroka Medical Center, Beer Sheva, Israel; Ben Gurion University of the Negev; Beer Sheva, Israel.
    Kaimakliotis, Ioannis P.
    Nicosia Private Practice, Nicosia, Cyprus.
    Valpiani, Daniela
    U.O. Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy.
    D'Incà, Renata
    Department of Surgical, Oncological and Gastroenterological Sciences, Azienda, University of Padua, Padova, Italy.
    Salupere, Riina
    Division of Gastroenterology, Tartu University Hospital, University of Tartu, Tartu, Estonia.
    Zammit, Stefania Chetcuti
    Division of Gastroenterology, Mater Dei Hospital, Msida, Malta.
    Ellul, Pierre
    Division of Gastroenterology, Mater Dei Hospital, Msida, Malta.
    Duricova, Dana
    IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.
    Bortlik, Martin
    IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic; Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
    Goldis, Adrian
    Clinic of Gastroenterology, University of Medicine ‘Victor Babes’, Timisoara, Romania.
    Kievit, Hendrika Adriana Linda
    Department of Medicine, Herning Central Hospital, Herning, Denmark.
    Toca, Alina
    Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova.
    Turcan, Svetlana
    Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova.
    Midjord, Jóngerð
    Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands.
    Nielsen, Kári Rubek
    Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands.
    Andersen, Karina Winther
    Medical Department, Regional Hospital of Viborg, Viborg, Denmark.
    Andersen, Vibeke
    Medical Department, Regional Hospital of Viborg, Viborg, Denmark; Focused Research Unit for Molecular Diagnostic and Clinical Research [MOK], IRS-Center Sonderjylland, Hospital of Southern Jutland, Aabenraa, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
    Misra, Ravi
    IBD Department, St Mark’s Hospital, London, UK.
    Arebi, Naila
    IBD Department, St Mark’s Hospital, London, UK.
    Oksanen, Pia
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; University of Tampere, Tampere, Finland.
    Collin, Pekka
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; University of Tampere, Tampere, Finland.
    de Castro, Luisa
    Department of Gastroenterology, Hospital Alvaro Cunqueiro, Instituto Investigación Sanitaria Galicia Sur, EOXI de Vigo, Vigo, Spain.
    Hernandez, Vicent
    Department of Gastroenterology, Hospital Alvaro Cunqueiro, Instituto Investigación Sanitaria Galicia Sur, EOXI de Vigo, Vigo, Spain.
    Langholz, Ebbe
    Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
    Munkholm, Pia
    Department of Gastroenterology, Nordsjællands Hospital, University of Copenhagen, Frederikssund, Denmark.
    Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study2019In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 13, no 2, p. 198-208Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.

    Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.

    Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].

    Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.

  • 25.
    Burisch, Johan
    et al.
    Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.
    Vegh, Zsuzsanna
    1st Department of Medicine, Semmelweis University, Budapest, Hungary.
    Katsanos, Konstantinnos H
    1st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece.
    Christodoulou, Dimitrios K
    1st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece.
    Lazar, Daniela
    Clinic of Gastroenterology, University of Medicine ‘Victor Babes’, Timisoara, Romania.
    Goldis, Adrian
    Clinic of Gastroenterology, University of Medicine ‘Victor Babes’, Timisoara, Romania.
    O'Morain, Colm
    Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College Dublin, Dublin, Ireland.
    Fernandez, Alberto
    Department of Gastroenterology. POVISA Hospital, Vigo, Spain.
    Pereira, Santos
    Department of Gastroenterology. Instituto de Investigación Sanitaria Galicia Sur, Estrutura Organizativa de Xestión Integrada de Vigo, Vigo, Spain.
    Myers, Sally
    IBD Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
    Sebastian, Shaji
    IBD Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
    Pedersen, Natalia
    Gastroenterology Department, Slagelse Hospital, Slagelse, Denmark.
    Olsen, Jóngerð
    Medical Department, National Hospital of the Faroe Islands, Torshavn, Denmark.
    Nielsen, Kári Rubek
    Medical Department, National Hospital of the Faroe Islands, Torshavn, Denmark.
    Schwartz, Doron
    Department of Gastroenterology and Hepatology, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
    Odes, Selwyn
    Department of Gastroenterology and Hepatology, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
    Almer, Sven
    Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Turk, Niksa
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb,Zagreb, Croatia.
    Cukovic-Cavka, Silvja
    Division of Gastroenterology and Hepatology, University Hospital Center Zagreb,Zagreb, Croatia.
    Nikulina, Inna
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
    Belousova, Elena
    Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
    Duricova, Dana
    IBD Clinical and Research Centre ISCARE, Charles University, Prague, Czech Republic.
    Bortlik, Martin
    IBD Clinical and Research Centre ISCARE, Charles University, Prague, Czech Republic; Institute of Pharmacology, 1st Medical Faculty, Charles University, Prague, Czech Republic.
    Shonová, Olga
    Gastroenterology Department, Hospital České Budějovice, České Budějovice, Czech Republic.
    Salupere, Riina
    Division of Gastroenterology, Tartu University Hospital,Tartu, Estonia.
    Barros, Louisa
    Department of Medicine, Hospital de Vale de Sousa, Porto, Portugal.
    Magro, Fernando
    Department of Gastroenterology, Hospital de São João, Porto, Portugal; Institute of Pharmacology and Therapeutics, Oporto Medical School, Porto, Portugal; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal.
    Jonaitis, Laimas
    Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Kupcinskas, Limas
    Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Turcan, Svetlana
    Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova.
    Kaimakliotis, Ioannis
    Nicosia private practice, Nicosia, Cyprus.
    Ladefoged, Karin
    Medical Department, Dronning Ingrids Hospital Greenland, Nuuk, Denmark.
    Kudsk, Karen
    Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
    Andersen, Vibeke
    Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
    Vind, Ida
    Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
    Thorsgaard, Niels
    Department of Medicine, Herning Central Hospital, Herning, Denmark.
    Oksanen, Pia
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
    Collin, Pekka
    Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
    Dal Piaz, Giulia
    Dipartimento Medicina Specialistica Gastroenterologia ed Endoscopia Digestiva, Ospedale Morgagni-Pierantoni, Forlì, Italy.
    Santini, Alessia
    Gastroenterology Unit, Careggi Hospital, Florence, Italy.
    Niewiadomski, Ola
    Department of Gastroenterology, St Vincent’s Hospital, Melbourne VIC, Australia.
    Bell, Sally
    Department of Gastroenterology, St Vincent’s Hospital, Melbourne VIC, Australia.
    Moum, Bjørn
    Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
    Arebi, Naila
    St Mark’s Hospital, Imperial College London, London, UK.
    Kjeldsen, Jens
    Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
    Carlsen, Katrine
    Department of Pediatrics, Hvidovre University Hospital, Hvidovre, Denmark.
    Langholz, Ebbe
    Department of Gastroenterology, Herlev Univerisity Hospital, Herlev, Denmark.
    Lakatos, Peter Laszlo
    1st Department of Medicine, Semmelweis University, Budapest, Hungary.
    Munkholm, Pia
    1st Department of Medicine, Semmelweis University, Budapest, Hungary.
    Gerdes, Lars Ulrik
    Center for Quality, Region of Southern Denmark, Middelfart, Denmark.
    Dahlerup, Jens Frederik
    Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
    The EpiCom study group, Group author
    Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort: An ECCO-EpiCom study2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no 10, p. 1213-1222Article in journal (Refereed)
    Abstract [en]

    Background and aims: Anaemia is an important complication of inflammatory bowel disease (IBD). The aim of this study was to determine the prevalence of anaemia and the practice of anaemia screening during the first year following diagnosis in a European prospective population-based inception cohort.

    Methods: Newly diagnosed IBD patients were included and followed prospectively for one year in 29 European and 1 Australian centre. Clinical data including demographics, medical therapy, surgery and blood samples were collected. Anaemia was defined according to the World Health Organization.

    Results: A total of 1,871 patients (CD: 686, 88%; UC: 1,021, 87%; IBDU 164. 81%) were included in the study. The prevalence of anaemia was higher in CD than in UC patients and overall, 49% of CD and 39% of UC patients had at least one instance of anaemia during the first 12 months after diagnosis. UC patients with more extensive disease and those from Eastern European countries, and CD patients with penetrating disease or colonic disease location, had higher risks of anaemia. CD and UC patients in need of none or only mild anti-inflammatory treatment had a lower risk of anaemia. In a significant proportion of patients, anaemia was not assessed until several months after diagnosis, and in almost half of all cases of anaemia a thorough work-up was not performed.

    Conclusions: Overall, 42% of patients had at least one instance of anaemia during the first year following diagnosis. Most patients were assessed for anaemia regularly; however, a full anaemia work-up was frequently neglected in this community setting.

  • 26.
    Burke, Kristin E.
    et al.
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston MA, USA; Harvard Medical School, Boston MA, USA.
    Ananthakrishnan, Ashwin N.
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, BostonMA, USA; Harvard Medical School, Boston MA, USA.
    Lochhead, Paul
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston MA, USA; Harvard Medical School, Boston MA, USA.
    Olen, Ola
    Pediatric Gastroenterology and Nutrition Unit, Sachs' Children's Hospital, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Ludvigsson, Jonas F.
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Richter, James M.
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Harvard Medical School, Boston MA, USA.
    Chan, Andrew T.
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston MA, USA; Harvard Medical School, Boston MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston MA, USA.
    Khalili, Hamed
    Gastroenterology Unit, Massachusetts General Hospital, Boston MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston MA, USA; Harvard Medical School, Boston MA, USA; Karolinska Clinical Epidemiology Unit, Karolinska Institutet, Solna, Sweden.
    Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no 5, p. 559-567Article in journal (Refereed)
    Abstract [en]

    Introduction: Long-term data on the influence of smoking on risk of microscopic colitis are limited. We therefore sought to examine and characterize the association between smoking and risk of incident microscopic colitis in two large prospective cohorts of women.

    Methods: We conducted a prospective study of 231,015 women enrolled in the Nurses' Health Study (NHS) and NHSII. Information regarding smoking, other lifestyle factors, and medications were collected biennially from 1976 to 2012 in NHS and 1989 to 2013 in NHSII. Incident cases of microscopic colitis were confirmed through physician medical record review. We used Cox proportional hazards modeling to examine the association between smoking and risk of microscopic colitis.

    Results: We documented 166 incident cases of microscopic colitis over 6,122,779 person-years of follow up. Compared to non-smokers, the multivariable-adjusted hazard ratio (HR) for microscopic colitis was 2.52 (95% CI 1.59 - 4.00) amongst current smokers and 1.54 (95% CI 1.09 - 2.17) amongst past smokers. The risk increased with higher pack-years of smoking (Ptrend = 0.001) and diminished following smoking cessation (Ptrend = 0.017). Current smoking appeared to be more strongly associated with risk of collagenous colitis (3.68; 95% CI 1.94 - 6.97) than lymphocytic colitis (HR 1.71; 95% CI 0.83 - 3.53).

    Conclusion: In two large prospective cohort studies, we observed an association between current smoking and risk of microscopic colitis. Risk of microscopic colitis appeared to increase with higher pack-years and diminish following smoking cessation. Future studies focused on characterizing the biologic mechanisms underlying these associations are warranted.

  • 27.
    Busch, Katharina
    et al.
    Dept Med Solna, Clin Epidemiol Unit, Karolinska Inst, Stockholm, Sweden.
    da Silva, Simone A.
    Dept Prevent Med, Univ Sao Paulo, Sao Paulo, Brazil.
    Holton, Michelle
    Lorimer Enterprises Inc, Red Deer AB, Canada.
    Rabacow, Fabiana M.
    Dept Prevent Med, Univ Sao Paulo, Sao Paulo, Brazil.
    Khalili, Named
    Digest Healthcare Ctr, Massachusetts Gen Hosp, Boston, USA.
    Ludvigsson, Jonas F.
    Örebro University Hospital. Dept Pediat, Örebro University Hospital, Örebro, Sweden; Dept Med Epidemiol & Biostat, Karolinska Inst, Stockholm, Sweden.
    Sick leave and disability pension in inflammatory bowel disease: A systematic review2014In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 8, no 11, p. 1362-1377Article, review/survey (Refereed)
    Abstract [en]

    Background & aims: Inflammatory bowel disease has considerable effects on work-related outcomes and leads to high societal costs due to sick leave and disability pension. The aims of this study were to systematically review evidence on work-related outcomes that are relevant to productivity losses and to evaluate whether medical or surgical interventions have a positive impact on patients work ability.

    Methods: A systematic literature search in PubMed was conducted in June 2013. Abstracts were screened by two independent reviewers, and full-text articles describing the frequency of work-related outcomes were retrieved. Two independent reviewers extracted data according to the PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses. Findings were organized by study design (non-interventional/interventional). Non-interventional studies were structured according to whether they presented data in comparison to control groups or not and interventional studies were summarized according to type of intervention.

    Results: This review included 30 non-interventional (15 with comparison groups and 15 without comparison group) and 17 interventional studies (9 surgical and 8 medical). The majority of the studies reported a high burden of work:related outcomes among inflammatory bowel disease patients regardless of the methodology used. While biologic agents showed positive effect on work absenteeism and presenteeism in randomized clinical trials, the impact of surgical interventions needs further evaluation.

    Conclusions: Inflammatory bowel disease patients experience a high burden in work-related outcomes. Additional data on productivity losses and the long-term impact of interventions is needed to help inform decision-makers about treatment options and their benefits in reducing productivity losses in inflammatory bowel disease patients. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

  • 28.
    Cars, Thomas
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiovascular epidemiology. Stockholm Cty Council, Publ Healthcare Serv Comm Adm, Stockholm, Sweden..
    Wettermark, Bjorn
    Stockholm Cty Council, Publ Healthcare Serv Comm Adm, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden..
    Lofberg, Robert
    Karolinska Inst, Dept Med, Stockholm, Sweden.;IBD Unit Sophiahemmet, Stockholm, Sweden..
    Eriksson, Irene
    Stockholm Cty Council, Publ Healthcare Serv Comm Adm, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden..
    Sundström, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology.
    Lordal, Mikael
    Karolinska Inst, Dept Med, Stockholm, Sweden.;Karolinska Univ Hosp, Ctr Digest Dis, Stockholm, Sweden..
    Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no 5, p. 556-565Article in journal (Refereed)
    Abstract [en]

    Crohn's disease [CD] and ulcerative colitis [UC] are chronic diseases associated with a substantial utilisation of healthcare resources. We aimed to estimate the prevalence of inflammatory bowel disease [IBD], CD, and UC and to describe and compare healthcare utilisation and drug treatment in CD and UC patients. This was a cross-sectional study of all patients with a recorded IBD diagnosis in Stockholm County, Sweden. Data on outpatient visits, hospitalisations, surgeries, and drug treatment during 2013 were analysed. A total of 13 916 patients with IBD were identified, corresponding to an overall IBD prevalence of 0.65% [CD 0.27%, UC 0.35%, inflammatory bowel disease unclassified 0.04%]; 49% of all IBD patients were treated with IBD-related drugs. Only 3.6% of the patients received high-dose corticosteroids, whereas 32.4% were treated with aminosalicylates [CD 21.2%, UC 41.0%, p < 0.0001]. More CD patients were treated with biologicals compared with UC patients [CD 9.6%, UC 2.9%, p < 0.0001] and surgery was significantly more common among CD patients [CD 3.0%, UC 0.8%, p < 0.0001]. This study indicates that patients with CD are the group with the highest medical needs. Patients with CD utilised significantly more healthcare resources [including outpatient visits, hospitalisations, and surgeries] than UC patients. Twice as many CD patients received immunomodulators compared with UC patients and CD patients were treated with biologicals three times more often. These results highlight that CD remains a challenge and further efforts are needed to improve care in these patients.

  • 29. Cesarini, M.
    et al.
    Collins, G.
    Rönnblom, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Santos, A.
    Sjöberg, Daniel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Parkes, M.
    Keshav, S.
    Travis, S.
    Predicting the risk of acute severe colitis (ASC) at diagnosis of Ulcerative Colitis (UC): external validation2015In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, no S1, p. S117-S118Article in journal (Other academic)
  • 30.
    Cesarini, Monica
    et al.
    Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England.;Sapienza Univ Rome, Dipartimento Med Interna & Specialita Med, Rome, Italy..
    Collins, Gary S.
    Univ Oxford, Ctr Stat Med, Oxford, England..
    Rönnblom, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Santos, Antonieta
    Cambridge Univ Hosp, Gastroenterol Unit, Cambridge, England.;Hosp Amato Lusitano, Gastroenterol Unit, Castelo Branco, Portugal..
    Wang, Lai Mun
    Oxford Univ Hosp, Dept Cellular Pathol, Oxford, England..
    Sjöberg, Daniel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Parkes, Miles
    Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England..
    Keshav, Satish
    Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England..
    Travis, Simon P. L.
    Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England..
    Predicting the Individual Risk of Acute Severe Colitis at Diagnosis2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no 3, p. 335-341Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Acute severe colitis [ASC] is associated with major morbidity. We aimed to develop and externally validate an index that predicted ASC within 3 years of diagnosis. Methods: The development cohort included patients aged 16-89 years, diagnosed with ulcerative colitis [UC] in Oxford and followed for 3 years. Primary outcome was hospitalization for ASC, excluding patients admitted within 1 month of diagnosis. Multivariable logistic regression examined the adjusted association of seven risk factors with ASC. Backwards elimination produced a parsimonious model that was simplified to create an easy-to-use index. External validation occurred in separate cohorts from Cambridge, UK, and Uppsala, Sweden. Results: The development cohort [Oxford] included 34/111 patients who developed ASC within a median 14 months [range 1-29]. The final model applied the sum of 1 point each for extensive disease, C-reactive protein [CRP] >10 mg/l, or haemoglobin < 12 g/dl F or < 14 g/dl M at diagnosis, to give a score from 0/3 to 3/3. This predicted a 70% risk of developing ASC within 3 years [score 3/3]. Validation cohorts included different proportions with ASC [Cambridge = 25/96; Uppsala = 18/298]. Of those scoring 3/3 at diagnosis, 18/18 [Cambridge] and 12/13 [Uppsala] subsequently developed ASC. Discriminant ability [c-index, where 1.0 = perfect discrimination] was 0.81 [Oxford], 0.95 [Cambridge], 0.97 [Uppsala]. Internal validation using bootstrapping showed good calibration, with similar predicted risk across all cohorts. A nomogram predicted individual risk. Conclusions: An index applied at diagnosis reliably predicts the risk of ASC within 3 years in different populations. Patients with a score 3/3 at diagnosis may merit early immunomodulator therapy.

  • 31.
    Christerson, Ulrika
    et al.
    University of Kalmar, School of Pure and Applied Natural Sciences.
    Keita, Åsa V
    Söderholm, Johan D
    Gustafson-Svärd, Christina
    University of Kalmar, School of Pure and Applied Natural Sciences.
    Increased expression of protease-activated receptor-2 in mucosal mast cells in Crohn's ileitis2009In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 3, no 2, p. 100-108Article in journal (Refereed)
    Abstract [en]

    Background and aims

    Activation of protease-activated receptor-2 (PAR-2) may stimulate various events of importance in inflammatory processes, including release of inflammatory mast cell mediators. PAR-2 is frequently up-regulated during inflammatory conditions, but it is not known if the expression is altered in Crohn's disease. The aim of the present study was to investigate the ileal mucosal PAR-2 expression in Crohn's ileitis, with particular emphasis on the expression in ileal mucosal mast cells.

    Methods

    Surgical specimens from the distal ileum were collected from patients with Crohn's ileitis and patients with colonic cancer as controls. The overall expression of PAR-2 was investigated by Western blot, and the presence of PAR-2 expressing mucosal mast cells by immunohistochemistry and cell counting. The effect of tumor necrosis factor-α (TNF-α) on the PAR-2 expression in a human mast cell line (HMC-1) was investigated by RT-PCR and immunocytochemistry.

    Results

    In Crohn's specimens, the fraction of PAR-2-expressing mucosal mast cells was increased about 2.5 times (P < 0.001; n = 14) compared with specimens from control patients (n = 6). No difference was found between inflamed (n = 6) and uninflamed Crohn's specimens (P > 0.05; n = 8). Exposure to TNF-α for 48 h up-regulated PAR-2 mRNA and protein expression in the HMC-1 cell line.

    Conclusion

    PAR-2 is up-regulated on ileal mucosal mast cells in Crohn's ileitis, possibly due to the action of inflammatory cytokines, such as TNF-α. This may contribute to perpetuating the inflammatory process in the intestinal mucosa in Crohn's ileitis.

  • 32.
    Christerson, Ulrika
    et al.
    University of Kalmar, School of Pure and Applied Natural Sciences.
    Keita, Åsa V
    Söderholm, Johan D
    Gustafson-Svärd, Christina
    University of Kalmar, School of Pure and Applied Natural Sciences.
    Potential role of protease-activated receptor-2-stimulated activation of cytosolic phospholipase A2 in intestinal myofibroblast proliferation: Implications for stricture formation in Crohn´s disease2009In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 3, no 1, p. 15-24Article in journal (Refereed)
    Abstract [en]

    Background and aims

    Myofibroblast hyperplasia contributes to muscularis mucosae thickening and stricture formation in Crohn's disease (CD). Protease-activated receptor-2 (PAR-2) and cytosolic phospholipase A2 (cPLA2) are known regulators of cell growth, but their significance in intestinal myofibroblast proliferation remain to be elucidated. The principle aims of the present study were to investigate if PAR-2 is expressed in the expanded muscularis mucosa in ileal CD specimens, if inflammatory cytokines may stimulate PAR-2 expression in intestinal myofibroblasts, and if PAR-2 and cPLA2 may regulate intestinal myofibroblast growth.

    Methods

    Immunohistochemistry was used for detection of PAR-2 in ileal CD specimens. Studies on PAR-2 expression, PLA2 activation and cell growth were performed in a human intestinal myofibroblast cell line, CCD-18Co. PAR-2 expression was investigated by RT-PCR and immunocytochemistry. PLA2 activity was analyzed by quantification of released 14C-arachidonic acid (14C-AA). Cell growth was examined by 3H-thymidine incorporation and cell counting.

    Results

    The thickened muscularis mucosae of the CD specimens showed strong PAR-2 expression. In cultured myofibroblasts, tumor necrosis factor-α (TNF-α) up-regulated PAR-2 mRNA and protein, and potentiated PAR-2-stimulated 14C-AA release by two known PAR-2 activators, trypsin and SLIGRL-NH2. The release of 14C-AA was dependent on cPLA2. Trypsin stimulated the proliferation of serum-starved cells, and inhibition of cPLA2 reduced normal cell growth and abolished the growth-promoting effect of trypsin.

    Conclusions

    The results suggest that PAR-2-mediated cPLA2 activation might be of importance in intestinal myofibroblast proliferation. The results also point to the possibility that PAR-2 up-regulation by inflammatory cytokines, like TNF-α, may modulate this effect.

     

     

     

     

     

  • 33. Dignass, Axel U
    et al.
    Gasche, Christoph
    Bettenworth, Dominik
    Birgegård, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Danese, Silvio
    Gisbert, Javier P
    Gomollon, Fernando
    Iqbal, Tariq
    Katsanos, Konstantinos
    Koutroubakis, Ioannis
    Magro, Fernando
    Savoye, Guillaume
    Stein, Jürgen
    Vavricka, Stephan
    European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases2015In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, no 3, p. 211-222Article in journal (Refereed)
  • 34.
    Eriksson, Carl
    et al.
    Örebro University, School of Medical Sciences.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences.
    Vigren, L.
    Dept Med, Div Gastroenterol, Hosp Trelleborg, Trelleborg, Sweden.
    Nilsson, L.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Visuri, Isabella
    Örebro University, School of Medical Sciences.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden; Dept Clin & Expt Med, Linköping, Sweden.
    Udumyan, Ruzan
    Örebro University, School of Medical Sciences.
    Almer, S.
    Dept Med, Gastrocentrum, Karolinska Inst, Stockholm, Sweden.
    Seddighzadeh, M.
    Merck Sharp & Dohme Ltd, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skane Univ Hosp, Lund, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S409-S410Article in journal (Other academic)
  • 35.
    Eriksson, Carl
    et al.
    Örebro University, School of Medical Sciences.
    Rundquist, Sara
    Örebro University, School of Medical Sciences.
    Cao, Yang
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Montgomery, Scott
    Örebro University, School of Medical Sciences.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort study2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S481-S481Article in journal (Other academic)
  • 36.
    Eriksson, Carl
    et al.
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Rundquist, Sara
    Örebro University, School of Medical Sciences.
    Lykiardopoulos, B.
    Department of Gastroenterology, Linköping University, Linköping, Sweden.
    Karlén, P.
    Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden.
    Grip, O.
    Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden.
    Söderman, C.
    Department of Internal Medicine, St Göran Hospital, Stockholm, Sweden.
    Almer, S.
    Department of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
    Hertervig, E.
    Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
    Gunnarsson, J.
    Department of Internal Medicine, Kungsbacka Hospital, Kungsbacka, Sweden.
    Delin, J.
    Department of Gastroenterology, Ersta hospital, Stockholm, Sweden.
    Strid, H.
    Department of Internal Medicine, Södra Älvsborgs Sjukhus, Borås, Sweden.
    Sjöberg, M.
    Department of Internal Medicine, Skaraborgs Hospital, Lidköping, Sweden.
    Öberg, D.
    Department of Internal Medicine, Sunderby Hospital, Sunderbyn, Sweden.
    Hjortswang, H.
    Department of Gastroenterology, Linköping University, Linköping, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S262-S263Article in journal (Refereed)
  • 37.
    Eriksson, Carl
    et al.
    Örebro University, School of Medical Sciences.
    Rundquist, Sara
    Örebro University, School of Medical Sciences.
    Lykiardopoulos, V.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Grip, O.
    Dept Gastroenterol, Skane Univ Hosp, Malmö, Sweden.
    Söderman, C.
    Dept Internal Med, St Goran Hosp, Stockholm, Sweden.
    Almer, S.
    Dept Med, Karolinska Inst, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skåne Univ Hosp, Lund, Sweden.
    Gunnarsson, J.
    Dept Internal Med, Kungsbacka Hosp, Kungsbacka, Sweden.
    Malmgren, C.
    Takeda Pharma AB, Solna, Sweden.
    Delin, J.
    Dept Gastroenterol, Ersta Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Sjöberg, M.
    Dept Internal Med, Skaraborgs Hosp, Lidköping, Sweden.
    Öberg, D.
    Dept Internal Med, Sunderby Hosp, Sunderbyn, Sweden.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences.
    Udumyan, Ruzan
    Örebro University, School of Medical Sciences.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linöping, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD)2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S494-S495Article in journal (Other academic)
  • 38.
    Eriksson, Carl
    et al.
    Örebro University, School of Medical Sciences.
    Rundquist, Sara
    Örebro University, School of Medical Sciences.
    Lykiardopoulos, V.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Grip, O.
    Dept Gastroenterol, Skåne Univ Hosp, Malmö, Sweden.
    Söderman, C.
    Dept Internal Med, St Göran Hosp, Stockholm, Sweden.
    Almer, S.
    Dept Med, Karolinska Inst, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skåne Univ Hosp, Lund, Sweden.
    Gunnarsson, J.
    Dept Internal Med, Kungsbacka Hosp, Kungsbacka, Sweden.
    Malmgren, C.
    Takeda Pharma AB, Solna, Sweden.
    Delin, J.
    Dept Gastroenterol, Ersta Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Sjöberg, M.
    Dept Internal Med, Skaraborgs Hosp, Lidköping, Sweden.
    Öberg, D.
    Dept Internal Med, Sunderby Hosp, Sunderbyn, Sweden.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences.
    Udumyan, Ruzan
    Örebro University, School of Medical Sciences.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences.
    Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S382-S383Article in journal (Other academic)
  • 39.
    Everhov, Åsa H.
    et al.
    Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Khalili, Hamed
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
    Askling, Johan
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Myrelid, Pär
    Division of Surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University, Linköping, Sweden; Department of Surgery, County Council of Östergötland, Linköping, Sweden.
    Ludvigsson, Jonas F.
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Nordenvall, C.
    Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Center for Digestive Disease, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden.
    Söderling, Jonas
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Olén, Ola
    Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Pediatric gastroenterology and Nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden.
    Neovius, Martin
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no 12, p. 1418-1428Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Crohn's disease may affect the ability to work and lead to permanent disability. We aimed to investigate work loss in prevalent patients.

    Methods: We identified patients with Crohn's disease and general population comparators matched by sex, birth year, healthcare region and education. We assessed days of sick leave and disability pension retrieved from the Swedish Social Insurance Agency and estimated the absolute and relative risk of receiving disability pension [minimum 25% work impairment].

    Results: In 2014, the 20638 Crohn's disease patients [median age 44 years] had more than twice as many mean lost workdays [disability pension: 44; sick leave: 19] as the 102038 comparators [disability pension: 20; sick leave: 8], mean difference 35 days [95% confidence interval 33-37]. However, the majority had no lost workdays [68% of patients and 85% of comparators]. The proportion of patients receiving disability pension was 15% (6.5% in the comparators, risk ratio 2.34 [2.25-2.43]) and was higher in all subgroups, especially in female patients [28% vs 13% in the comparators], in those with ≤9 years of education [41% vs 23%] and in ages 60-64 years [46% vs 25%]. The relative risk of disability pension within the patient cohort [adjusted for age, sex, region and education] was higher in patients with complicated disease behaviour, extraintestinal manifestations, need of surgery or treatment with biologics. The differences between patients and comparators remained when comparing other calendar years [2006-2013].

    Conclusion: Work loss was found in approximately one-third of patients. The mean number of lost workdays was twice as high as in the comparators.

  • 40.
    Everhov, Åsa H.
    et al.
    Soder Sjukhuset, Sweden; Karolinska Inst, Sweden.
    Khalili, Hamed
    Karolinska Inst, Sweden; Harvard Med Sch, MA USA.
    Askling, Johan
    Karolinska Inst, Sweden.
    Myrelid, Pär
    Linköping University, Department of Clinical and Experimental Medicine, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Ludvigsson, Jonas F.
    Karolinska Inst, Sweden; Univ Orebro, Sweden.
    Halfvarson, Jonas
    Univ Orebro, Sweden.
    Nordenvall, Caroline
    Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
    Soderling, Jonas
    Karolinska Inst, Sweden.
    Olen, Ola
    Soder Sjukhuset, Sweden; Karolinska Inst, Sweden; Sachs Children and Youth Hosp, Sweden.
    Neovius, Martin
    Karolinska Inst, Sweden.
    Sick Leave and Disability Pension in Prevalent Patients With Crohns Disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no 12, p. 1418-1428Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Crohns disease may affect the ability to work and lead to permanent disability. We aimed to investigate work loss in prevalent patients. Methods: We identified patients with Crohns disease and general population comparators matched by sex, birth year, healthcare region and education. We assessed days of sick leave and disability pension retrieved from the Swedish Social Insurance Agency and estimated the absolute and relative risk of receiving disability pension [minimum 25% work impairment]. Results: In 2014, the 20 638 Crohns disease patients [median age 44 years] had more than twice as many mean lost workdays [disability pension: 44; sick leave: 19] as the 102 038 comparators [disability pension: 20; sick leave: 8], mean difference 35 days [95% confidence interval 33-37]. However, the majority had no lost workdays [68% of patients and 85% of comparators]. The proportion of patients receiving disability pension was 15% (6.5% in the comparators, risk ratio 2.34 [2.25-2.43]) and was higher in all subgroups, especially in female patients [28% vs 13% in the comparators], in those with amp;lt;= 9 years of education [41% vs 23%] and in ages 60-64 years [46% vs 25%]. The relative risk of disability pension within the patient cohort [adjusted for age, sex, region and education] was higher in patients with complicated disease behaviour, extraintestinal manifestations, need of surgery or treatment with biologics. The differences between patients and comparators remained when comparing other calendar years [2006-2013]. Conclusion: Work loss was found in approximately one-third of patients. The mean number of lost workdays was twice as high as in the comparators.

  • 41.
    Forkel, Marianne
    et al.
    Karolinska Inst, Sweden.
    van Tol, Sophie
    Karolinska Inst, Sweden.
    Hoog, Charlotte
    Karolinska Inst, Sweden.
    Michaelsson, Jakob
    Karolinska Inst, Sweden.
    Almer, Sven
    Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
    Mjösberg, Jenny
    Linköping University, Department of Clinical and Experimental Medicine, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Karolinska Inst, Sweden.
    Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohns Disease and Ulcerative Colitis2019In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 13, no 1, p. 67-78Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Innate lymphoid cells [ILC] have been suggested to play a role in inflammatory bowel disease [IBD]. Here, we investigated the ILC compartment in intestinal biopsies and blood from distinct patient groups with Crohns disease [CD] and ulcerative colitis [UC], either newly diagnosed or with disease established for at least 1 year. This approach allowed us to simultaneously investigate temporal, disease-specific, and tissue-specific changes in ILC composition in IBD. Methods: ILC subset frequencies, phenotype, and transcription factor profile in blood and intestinal biopsies were investigated by multi-parameter flow cytometry analysis. Endoscopic disease severity was judged using the ulcerative colitis endoscopic index of severity and the simple endoscopic score for Crohns disease. Results: The frequency of NKp44(+)ILC3 was decreased in inflamed tissue, both in patients with CD and those with UC, already at the time of diagnosis, and correlated with disease severity. Simultaneously, the frequency of ILC1 was increased in patients with CD, whereas the frequency of ILC2 was increased in patients with UC. However, in patients with established UC or CD, both ILC1 and ILC2 were increased. In contrast to the ILC composition in inflamed tissue, ILC in non-inflamed tissue or blood were unchanged compared with non-IBD controls. Finally, in patients undergoing treatment with an anti-alpha(4)beta(7) antibody the frequencies of ILC in peripheral blood remained unchanged. Conclusions: We report both shared and distinct changes in ILC composition depending on diagnosis and disease duration. The alterations in ILC composition in IBD occur selectively at inflamed sites in the gut.

  • 42.
    Frigstad, S. O.
    et al.
    Vestre Viken Hosp Trust, Dept Med, Baerum Hosp, Drammen, Norway.;Ostfold Hosp Trust, Dept Res, Gralum, Norway.;Univ Oslo, Inst Clin Med, Oslo, Norway..
    Hammarlund, P.
    Angelholms Hosp, Dept Med, Angelholm, Sweden..
    Bonderup, O.
    Silkeborg Reg Hosp, Dept Gastroenterol, Silkeborg, Denmark..
    Rannem, T.
    Nordsjaelland Hosp, Dept Gastroenterol, Hillerod, Denmark..
    Haaber, A.
    Herlev Gentofte Hosp, Dept Gastroenterol, Hellerup, Denmark..
    Fallingborg, J.
    Aalborg Univ Hosp, Dept Med Gastroenterol, Aalborg, Denmark..
    Blom, H.
    Sunderby Hosp, Dept Med, Lulea, Sweden..
    Bajor, A.
    Sahlgrens Univ Hosp, Dept Internal Med, Gothenburg, Sweden.;SAS, Dept Med, Boras, Sweden..
    Hellström, Per M.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, p. S351-S351Article in journal (Other academic)
  • 43. Frigstad, S. O.
    et al.
    Rannem, T.
    Hellström, Per M.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Hammarlund, P.
    Bonderup, O.
    A Scandinavian prospective observational study of iron isomaltoside 1000 treatment: Clinical practice and outcomes in iron deficiency anaemia in patients with IBD2015In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, no S1, p. S320-S320Article in journal (Other academic)
  • 44.
    Gerdin, Linda
    et al.
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping. Department of Surgery, Höglandssjukhuset, Eksjö, Sweden.
    Eriksson, Anders S.
    Sahlgrens University Hospital, Sweden.
    Olaison, Gunnar
    Northern Hospital Zeeland, Denmark.
    Sjödahl, Rune
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Ström, Magnus
    Linköping University, Department of Clinical and Experimental Medicine, Division of Neuro and Inflammation Science. Region Östergötland, Heart and Medicine Center, Department of Gastroentorology. Linköping University, Faculty of Medicine and Health Sciences.
    Söderholm, Johan D
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping.
    Myrelid, Pär
    Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Surgery in Linköping. Linköping University, Faculty of Medicine and Health Sciences.
    The Swedish Crohn Trial: A Prematurely Terminated Randomized Controlled Trial of Thiopurines or Open Surgery for Primary Treatment of Ileocaecal Crohns Disease2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no 1, p. 50-54Article in journal (Refereed)
    Abstract [en]

    Background and aims: The importance of efficient and safe treatment of Crohns disease is highlighted by its chronicity. Both medical and surgical treatments have shown good results in the symptomatic control of limited ileocaecal Crohns disease. The aim of this study was to compare medical treatment with surgical treatment of ileocaecal Crohns disease. Methods: Thirty-six patients from seven hospitals with primary ileocaecal Crohns disease were randomized to either medical or surgical treatment. The medical treatment was induction of remission with budesonide and thereafter maintenance treatment with azathioprine. The surgical treatment was open ileocaecal resection. Crohns disease activity index over time, expressed as area under the curve at 1, 3 and 5 years, was the primary endpoint. Subjective health measured with the 36-item Short Form Survey Instrument (SF36) and a visual analogue scale (VAS) were secondary endpoints. Results: There were no differences between the treatment groups in Crohns disease activity index over time. General health, measured as SF36 score, was higher in patients receiving surgical treatment than in those receiving medical treatment at 1 year, but there was no corresponding difference in VAS. Due to the slow inclusion rate and changes in clinical practice, the study was t = erminated prematurely. Conclusion: The study ended up being underpowered and should be interpreted with caution, but there was no clinically significant difference between the two treatment arms. Further studies are needed to address this important clinical question.

  • 45.
    Heap, Graham A.
    et al.
    BD Pharmacogenetics, Royal Devon and Exeter Foundation Trust, Exeter, UK; Precision Medicine Exeter, University of Exeter, Exeter, UK .
    Halfvarson, Jonas
    Örebro University, School of Medicine, Örebro University, Sweden. Department of Gastroenterology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
    Ahmad, Tariq
    BD Pharmacogenetics, Royal Devon and Exeter Foundation Trust, Exeter, UK; Precision Medicine Exeter, University of Exeter, Exeter, UK .
    Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease2016In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, no 2, p. 149-158Article in journal (Refereed)
    Abstract [en]

    Background and Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically useful genetic markers so that these drugs can be avoided or so that monitoring can be intensified in high-risk patients.

    Methods: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion criteria included normal renal function prior to commencing 5-ASA, >= 50% rise in creatinine any time after starting 5-ASA, and physician opinion implicating 5-ASA strong enough to justify drug withdrawal. An adjudication panel identified definite and probable cases from structured case report forms. A genome-wide association study was then undertaken with these cases and 4109 disease controls.

    Results: After adjudication, 151 cases of 5-ASA-induced nephrotoxicity were identified. Sixty-eight percent of cases were males, with nephrotoxicity occurring at a median age of 39.4 years (range 6-79 years). The median time for development of renal injury after commencing 5-ASA was 3.0 years (95% confidence interval [CI] 2.3-3.7). Only 30% of cases recovered completely after drug withdrawal, with 15 patients requiring permanent renal replacement therapy. A genome-wide association study identified a suggestive association in the HLA region (p = 1 x 10(-7)) with 5-ASA-induced nephrotoxicity. A sub-group analysis of patients who had a renal biopsy demonstrating interstitial nephritis (n = 55) significantly strengthened this association (p = 4 x 10(-9), odds ratio 3.1).

    Conclusions: This is the largest and most detailed study of 5-ASA-induced nephrotoxicity to date. It highlights the morbidity associated with this condition and identifies for the first time a significant genetic predisposition to drug-induced renal injury.

  • 46.
    Hellström, Per M.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Al-Saffar, Anas K.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Tartera Diaz, Hetzel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Gannavarapu, Venkata Ram
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Webb, Dominic-Luc
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNF alpha in response to infliximab in Crohn’s disease2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no suppl 1, p. S389-S389Article in journal (Refereed)
  • 47.
    Hellström, Per M.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Diaz, Hetzel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Lönnkvist, Maria
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Befrits, R.
    Fecal calprotectin and serum C-reactive protein predict outcome of infliximab induction therapy in inflammatory bowel disease2015In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, no S1, p. S287-S288Article in journal (Other academic)
  • 48.
    Hellström, Per M.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Lonnkvist, M.
    Karolinska Inst, Med, Stockholm, Sweden..
    Tartera, Hetzel O. Diaz
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Befrits, R.
    Karolinska Inst, Med, Stockholm, Sweden..
    Holst, M.
    Karolinska Inst, Womens & Childrens Hlth, Stockholm, Sweden..
    Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, p. S310-S311Article in journal (Other academic)
  • 49.
    Hellström, Per M.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Stålhammar, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Beydogan, H.
    QuintilesIMS, Real World Evidence Solut & HEOR, Solna, Sweden..
    Huetson, P.
    QuintilesIMS, Real World Evidence Solut & HEOR, Solna, Sweden..
    Skup, M.
    AbbVie Inc, N Chicago, IL USA..
    Agreus, L.
    Karolinska Institute.
    Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, p. S457-S457Article in journal (Other academic)
  • 50.
    Hindorf, Ulf
    et al.
    Skåne University Hospital, Lund, Sweden.
    Lindqvist Appell, Malin
    Linköping University, Department of Medical and Health Sciences, Clinical Pharmacology. Linköping University, Faculty of Health Sciences.
    Letter: TPMT status determination: The simplest is the most effective? Reply: Reply to Dr. Chouchana's letter2012In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 6, no 7, p. 808-808Article in journal (Other academic)
12 1 - 50 of 98
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf